Agios Pharmaceuticals (AGIO) Non-Current Deffered Revenue (2012 - 2019)

Agios Pharmaceuticals' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $50.6 million for Q4 2019.

• Quarterly Non-Current Deffered Revenue fell 15.43% year-over-year to $50.6 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $50.6 million (down 15.43% YoY) and the FY2019 annual result came in at $50.6 million, down 15.43% from the prior year.
• Non-Current Deffered Revenue was $50.6 million for Q4 2019 at Agios Pharmaceuticals, down from $55.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $173.9 million in Q3 2016 and bottomed at $133000.0 in Q1 2015.
• A 5-year average of $59.9 million and a median of $34.3 million in 2018 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2016 — Non-Current Deffered Revenue soared 1365.41% — and 2018, when it sank 87.45%.
• Agios Pharmaceuticals' Non-Current Deffered Revenue stood at $17.4 million in 2015, then jumped by 788.81% to $154.3 million in 2016, then dropped by 18.47% to $125.8 million in 2017, then tumbled by 52.46% to $59.8 million in 2018, then declined by 15.43% to $50.6 million in 2019.
• Business Quant data shows AGIO's Non-Current Deffered Revenue at $50.6 million in Q4 2019, $55.0 million in Q1 2019, and $59.8 million in Q4 2018.